Annual Working Capital
$617.16 M
+$256.13 M+70.94%
31 March 2024
Summary:
Immunovant annual working capital is currently $617.16 million, with the most recent change of +$256.13 million (+70.94%) on 31 March 2024. During the last 3 years, it has risen by +$226.93 million (+58.15%). IMVT annual working capital is now at all-time high.IMVT Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Working Capital
$440.72 M
-$103.31 M-18.99%
30 September 2024
Summary:
Immunovant quarterly working capital is currently $440.72 million, with the most recent change of -$103.31 million (-18.99%) on 30 September 2024. Over the past year, it has increased by +$189.80 million (+75.64%). IMVT quarterly working capital is now -35.06% below its all-time high of $678.67 million, reached on 31 December 2023.IMVT Quarterly Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IMVT Working Capital Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +70.9% | +75.6% |
| 3 y3 years | +58.1% | -17.7% |
| 5 y5 years | +10000.0% | +10000.0% |
IMVT Working Capital High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +70.9% | -35.1% | +75.6% |
| 5 y | 5 years | at high | >+9999.0% | -35.1% | >+9999.0% |
| alltime | all time | at high | >+9999.0% | -35.1% | >+9999.0% |
Immunovant Working Capital History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $440.72 M(-19.0%) |
| June 2024 | - | $544.03 M(-11.8%) |
| Mar 2024 | $617.16 M(+70.9%) | $617.16 M(-9.1%) |
| Dec 2023 | - | $678.67 M(+170.5%) |
| Sept 2023 | - | $250.92 M(-16.0%) |
| June 2023 | - | $298.66 M(-17.3%) |
| Mar 2023 | $361.04 M(-22.9%) | $361.04 M(-12.6%) |
| Dec 2022 | - | $413.16 M(+4.8%) |
| Sept 2022 | - | $394.31 M(-9.4%) |
| June 2022 | - | $435.06 M(-7.1%) |
| Mar 2022 | $468.41 M | $468.41 M(-7.1%) |
| Dec 2021 | - | $504.13 M(-5.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2021 | - | $535.41 M(+47.0%) |
| June 2021 | - | $364.30 M(-6.6%) |
| Mar 2021 | $390.24 M(+316.2%) | $390.24 M(-5.5%) |
| Dec 2020 | - | $412.94 M(-5.6%) |
| Sept 2020 | - | $437.46 M(+64.1%) |
| June 2020 | - | $266.57 M(+184.3%) |
| Mar 2020 | $93.76 M(<-9900.0%) | $93.76 M(-16.1%) |
| Dec 2019 | - | $111.81 M(+7747.1%) |
| Sept 2019 | - | $1.42 M(-28.1%) |
| June 2019 | - | $1.98 M(-1399.3%) |
| Mar 2019 | - | -$152.60 K |
| Dec 2018 | -$55.40 K | - |
FAQ
- What is Immunovant annual working capital?
- What is the all time high annual working capital for Immunovant?
- What is Immunovant annual working capital year-on-year change?
- What is Immunovant quarterly working capital?
- What is the all time high quarterly working capital for Immunovant?
- What is Immunovant quarterly working capital year-on-year change?
What is Immunovant annual working capital?
The current annual working capital of IMVT is $617.16 M
What is the all time high annual working capital for Immunovant?
Immunovant all-time high annual working capital is $617.16 M
What is Immunovant annual working capital year-on-year change?
Over the past year, IMVT annual working capital has changed by +$256.13 M (+70.94%)
What is Immunovant quarterly working capital?
The current quarterly working capital of IMVT is $440.72 M
What is the all time high quarterly working capital for Immunovant?
Immunovant all-time high quarterly working capital is $678.67 M
What is Immunovant quarterly working capital year-on-year change?
Over the past year, IMVT quarterly working capital has changed by +$189.80 M (+75.64%)